[Postoperative and adjuvant intravesical therapy of superficial bladder tumours. Clinical practice and applied therapeutic agents].
BACKGROUND
The aim of this questionnaire was to obtain an impression of the practice and applied therapeutic agents in postoperative and adjuvant intravesical therapy of superficial bladder tumours.


METHODS
Standardised questionnaires answered by urologists about instillation therapy in 351 patients were analysed.


RESULTS
Results showed a discrepancy between the clinical practice and the guidelines in respect of the postoperative instillations and the use of BCG immunotherapy, respectively.


CONCLUSIONS
It does not seem to be standard practice to treat every patient with one immediate post-operative instillation. Only a minority of high-risk patients received intravesical BCG instillations. Substances mainly used for instillation therapy were mitomycin C and doxorubicin.
Lingnau
Anja
A
Urologische Klinik und Hochschulambulanz, Charité-Universitätsmedizin Berlin, Berlin. anja.lingnau@charite.de
Miller
K
K
Steiner
U
U
Jentzmik
F
F
Weikert
S
S
Schostak
M
M
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D011379:Prognosis; D011795:Surveys and Questionnaires; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D016685:Mitomycin; D004317:Doxorubicin